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Background
Worldwide, breast cancer is the leading cause of cancer-
related deaths in women (American Cancer Society, 2007).
Several genes, including the well-characterized BRCA1
and BRCA2, are known to be involved in breast carcino-
genesis (Campeau et al., 2008; Loman et al., 2001).
Although research continues on known genes to further
understand breast cancer development, there has also been
emerging interest in researching epigenetics and gene reg-
ulation. One of the most surprising recent progresses in
understanding the mechanisms of gene regulation has
been the discovery of microRNAs (miRNAs) (Wightman
et al., 1993). miRNAs are short, single-stranded RNAs of
~22 nucleotides that do not code for proteins themselves.
miRNAs alter gene expression at a post-transcriptional
level, regulating the amount of protein expressed from
coding RNAs. Their regulatory effect is based on base
pairing with mRNAs at the 3’-untranslated region, result-
ing in translational repression, or at the open reading
frame, resulting in cleavage and degradation of the mRNA
(Verghese et al., 2008). It has been reported that a single
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miRNA potentially binds to hundreds of mRNA targets
and thus might down-regulate genes with different func-
tions (Lim et al., 2005). It is estimated that one third of
human genes are potential targets of miRNAs (Esquela-
Kerscher & Slack, 2006). miRNAs are believed to play an
important role in numerous biological processes, includ-
ing development, metabolism, cell proliferation,
differentiation and apoptosis (Davalos & Esteller).
Recent evidence indicates that miRNAs may also act as
tumor suppressors and oncogenes, depending on which
gene(s) they modulate (Zhang et al., 2007). miRNAs that
negatively regulate tumor suppressor genes, or genes that
control cell differentiation and apoptosis, may function as
oncogenes if over-expressed in cancers. On the other
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hand, miRNAs that act as tumor suppressor genes by
down-regulating oncogenes may lead to loss of oncogenic
regulation if under-expressed in cancers (Zhang et al.,
2007). Altered miRNAs, either in terms of structural
changes or in the quantity of mature miRNAs, have been
linked to cancer risk (Esquela-Kerscher & Slack, 2006). A
recent paper identified a general decrease of mature
miRNA levels in different kinds of human cancers com-
pared with normal tissues (Lu et al., 2005). In breast
cancer several miRNAs, including miR-196a, have been
observed to be aberrantly expressed in breast cancer tissue
compared with normal breast tissue (Iorio et al., 2005).
miR-196a was highly expressed in breast cancer tissue
(Iorio et al., 2005). It is plausible that variations such as
mutations or single nucleotide polymorphisms (SNPs) in
miRNAs which affect expression levels may play a role in
breast cancer development.
SNPs in miRNA genes may alter miRNA expression
and/or function, because miRNA binding to its mRNA
target is dependent on sequence complementarity with
the target. The SNP rs11614913 C>T in hsa-miR-196a-2
has been implicated in lung cancer susceptibility (Tian et
al., 2009). Two studies have also recently reported that
this variant might be linked to breast cancer susceptibil-
ity (Hoffman et al., 2009; Hu et al., 2009). These two
case-control studies demonstrated that the C-allele was
significantly associated with increased breast cancer risk
in both a Chinese population (Hu et al., 2009) and a US
population (Hoffman et al., 2009). To build upon these
findings, this study investigated whether there is an asso-
ciation between rs11614913 C>T and breast cancer




The study utilized 193 females diagnosed with breast
cancer and 190 controls. The affected and control popula-
tions were matched for age and all were of Caucasian
ethnicity as previously described (Curran et al., 2002).
Briefly, this consisted of participant reporting of parental
and grandparental ethnicity. The exclusion criteria for
both included previous cancer or a family history of
cancer, as determined by participant reporting. No other
risk factors were controlled for. Samples were recruited
through collaboration with the Gold Coast Hospital.
Additional affected samples, as well as the entire control
population, were obtained through the Genomics
Research Centre (GRC) at Griffith University through vol-
unteers responding to advertisements. Samples consisted
of peripheral blood taken by GRC of hospital staff. All
patients gave informed consent. The study was conducted
under the approval of the Gold Coast Hospital and
Griffith University Ethics Committees.
Genotyping
The SNP in this study was indentified in a previous study by
Hu et al. (2009) and genotyped using a Polymerase chain
reaction (PCR)-restriction length polymorphism assay. SNP
analysis was carried out using GoTaq DNA Polymerase
(Promega, USA) and Hpy188I (New England Biolabs, USA).
The assays were carried out following the instructions from
the company. The sequences of the forward primer and the
reverse primer were 5’-GGGCTGAATTTCTTCCTTCC-3’
and 5’-CTCGACGAAAACCGACTGAT-3’, respectively. PCR
amplification was performed in a 24-µl reaction mixture
containing 60ng genomic DNA, 0.2µM each primer, 0.33mM
dNTPs, 1X GoTaq buffer, 5.42 mM MgCl2 and GoTaq poly-
merase. The reaction conditions were as follows; 95°C for 2
minutes, and 35 cycles of 95°C for 45 seconds, 59°C for 1
minute, and 72°C for 45 seconds, followed by 7 min at 72°C.
Following amplification, 10µl of product was digested with
the restriction enzyme Hpy188I at 37°C for 4 hours. Samples
were then loaded into an ethidium bromide-stained 3%
agarose gel for genotype determination.
To assure the quality of genotyping, the RFLP assay was
performed in a 96-well PCR plate, each containing three
positive controls of DNA samples with known genotypes
(CC, CT, TT). The concordance rate was 100%. DNA
quality or quantity of 6 breast cancer samples and 19
control samples was insufficient for genotyping. Therefore
the final analysis included 187 cases and 171 controls.
Statistical Analysis
To determine whether any significant differences in poly-
morphism frequencies occurred between the case and
control population, allele and genotype frequencies were
compared using the chi-square method. Both cases and
controls were also analyzed to determine if they were in
Hardy-Weinberg Equilibrium. Furthermore, odds ratios
(ORs) with their 95% Confidence Interval (CI) were cal-
culated to evaluate the potential association between
rs11614913 and breast cancer susceptibility.
Results
We genotyped rs11614913 in both the affected group and
the control group. The frequencies of the genotypes and
alleles are listed in Table 1. The CC genotype was slightly
more common in the breast cancer population, but in
general both populations showed a similar distribution of
genotypes. Chi-Square analysis of this data showed that no
significant difference was observed between the breast
cancer group and the control group samples for genotypes
(χ2 = 0.24, P = 0.888) or for alleles (χ2 = 0.16, P = 0.691).
Hardy-Weinberg equilibrium analysis was performed to
exclude the possibility of experimental artefacts. We found
that both cases (χ2 = 0.41, p = .52) and controls (χ2 = 0.05,
P = 0.83) were in HWE. ORs were calculated (Table 2) and
showed no association of rs11614913 with breast cancer
susceptibility.
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Since our cohort was comprised of Caucasians, we com-
pared our control genotype frequencies for rs11614913
with those in a European population (HapMap) and found
that the two populations corresponded closely (Table 3).
Discussion
Hoffman et al. showed in a cell based assay, that the
variant allele T had an effect on miR-196a levels in vitro
(Hoffman et al., 2009); they were decreased compared
with miR-196a-C. Furthermore they demonstrated in a
whole-genome expression microarray (using RNA isolated
from cells transfected with a pre-miR-196a-C, pre-miR-
196a-T, and an empty vector) that miR-196a-C had a
significantly greater impact on gene expression than mir-
196a-T, suggesting that the variant has a diminished
regulatory capacity (Hoffman et al., 2009). Among the
genes that were differently expressed after enforced expres-
sion of pre-miR-196a-C were several potential tumor
suppressors and oncogenes (Hoffman et al., 2009).
According to this data it is plausible that miR-196a may
have oncogenic properties.
A recent meta-analysis evaluated the association
between rs11614913 hsa-miR-196a-2 and breast cancer
risk and included four studies with four different cohorts
(Gao et al., 2011). The meta-analysis showed that
rs11614913 polymorphisms significantly increased breast
cancer risk for the C allele in the homozygote comparison
(CC versus TT, OR = 1.30; 95% CI, 1.01-1.68) and the
dominant model (CC versus CT/TT, OR = 1.11; 95% CI,
1.01-1.23) (Table 2).
In this case-control study of breast cancer in Caucasian
women, we found that the common SNP rs11614913 was
not associated with increased risk of breast cancer.
Although the CC genotype frequency was higher in the
breast cancer population, the ORs were not significant
(CC versus TT, OR = 1.10; 95%CI, 0.60–2.01) and (CC
versus CT/TT, OR = 1.11; 95% CI, 0.72–1.72) (Table 2).
No significant P-values were found.
Our data contradict the findings of Hu et al. (Hu et al.,
2009) and Hoffman et al. (2009), who both found a signif-
icant association between rs11614913 and breast cancer
risk. The discrepancy between our results and these might
be explained by population-specific factors, such as differ-
ent genetic background, lifestyle, or environmental factors.
For instance, the allelic frequency of rs11614913 is differ-
ent between Han Chinese and Caucasian populations
(Table 3). Whereas in the Chinese controls studied by Hu
et al. (2009) the minor allele frequency of rs11614913 was
0.44 (C allele), the C allele was the common one in our
Caucasian controls with a frequency of 0.58. In the case of
Hoffman’s study the participants were not matched for
ethnicity. Although the population was predominantly
Caucasian, ethnical diversity may have been crucial for the
outcome of the study and certainly there seem to be ethnic
differences in the allele frequencies associated with this
SNP (Table 3). The results of Hoffman et al. did hold
when only Caucasians were considered, but we do not
know whether minor ethnic differences between our and
their study may still be influencing the outcome. An addi-
tional and perhaps more important factor is that most of
Hoffman’s controls were diagnosed with benign breast
diseases, which might be providing a subpopulation of
controls with higher resistance to malignant transforma-
tion as opposed to dysplasia, influencing the outcome,
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TABLE 1
Analysis Results, Allele and Genotype Frequencies for Tested SNP
rs11614913 Allele frequency Genotype frequency
Group Frequency C T CC CT TT Total
Breast Cancer N 222 152 68 86 33 187
% 59.36 40.64 36.36 45.99 17.65
Control N 198 144 58 82 31 171
% 57.89 42.11 33.92 47.95 18.13
(χ2 = 0.16, P = .691) (χ2 = 0.24, P = .888)
TABLE 2
Results of ORs in the Meta-Analysis and our Caucasian Population
Polymorphism Cases/controls OR (95% Confidence Interval)
CC vs. CT CC vs. TT CC vs. CT/TT CC/CT vs. TT
meta-analysis rs11614913 3287/4298 1.08 1.30* 1.11* 1.22
(Gao et al., 2011) (0.97–1.19) (1.01–1.68) (1.01–1.23) (1.00–1.50)
Queensland rs11614913 187/171 1.12 1.10 1.11 1.03
(0.70–1.78) (0.60–2.01) (0.72–1.72) (0.60–1.78)
Note: *Bold-faced values indicate significant difference at α = 0.05 level.
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particularly if rs11614913 can affect malignant transfor-
mation as their own results suggest.
On these lines, it is possible that genetic variants in the
genes that miR-196a targets may contribute to its ability to
influence breast cancer risk. Altered sequence in target
mRNAs, including SNPs previously overlooked for being
non-amino acid changing may enhance or reduce the
ability of the miR-196a to block translation. Differences in
SNP frequency between our population and those of Hu
et al. and Hoffman et al. may explain why this study did
not detect any association with breast cancer risk. Our
population size is also smaller than both studies and it
may also be that the effect of the rs11614913 SNP on
breast cancer risk is relatively weak and thus a larger
sample size may be needed to detect it.
However, our data do correspond well with the findings
of Catucci et al. (2009), who genotyped an Italian and a
German cohort, comprised of 2,003 and 2,651 partici-
pants, respectively. According to their data, there was a
lack of association between rs11614913 and breast cancer
risk. In terms of genotype frequencies both of these popu-
lations were similar to our Australian cohort, as the
C-allele was the predominant allele. As both of the sub-
populations in the Catuccu et al. study were larger than
that of Hoffman et al., it is likely that the risk profile for
rs11614913 is complex and that, despite the smaller size,
this study reinforces that possibility.
Although our results did not suggest any association of
rs11614913 in miR-196a with breast cancer risk, there has
been evidence that miR-196a may play an important role
in carcinogenesis. Potential targets of miR-196a have been
identified, among them are genes that participate in
diverse cancer-related pathways (Yekta et al., 2004); The
cleavage of HOX gene products like HOXB8 mRNA was
shown to be partly the result of miR-196a (Yekta et al.,
2004). HOX genes regulate several genes that in turn regu-
late large networks of other genes, thus are involved in
several crucial biological processes. In addition, LSP1 and
TOX3 are potential targets of miR-196a as determined by
the mirBase database (http://www.mirBase.org). These
two are novel breast cancer susceptibility genes that have
been recently discovered in a whole-genome association
study (Easton et al., 2007). The roles of these genes in
breast cancer development remain to be investigated, but
the rs11614913 SNP may modulate that role.
Conclusion
miRNAs play an important role in many biological
processes. A better understanding of their pathways, their
mechanisms and their targets could lead to progress in
breast cancer prognosis, classification, and treatment. At
present, little is known about whether SNPs in miRNAs
can alter breast cancer risk. Therefore, future characterisa-
tion of SNPs of miRNAs may help to investigate their
contribution to cancer development.
Our data suggested lack of association between SNP
rs11614913 in hsa-mir-196a-2 and breast cancer risk. As
there is a discrepancy between our results and previous
findings, it is important to assess the role of rs11614913 in
breast cancer by further larger studies investigating differ-
ent ethnic groups. Functional studies should also attempt
to more closely probe the mechanisms behind hsa-mir-
196a-2 function to help inform good recruiting
methodologies for future susceptibility studies.
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